Zhongyi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhongyi Xu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Leihong Xiang
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
17 shared publications - Chengfeng Zhang
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China
16 shared publications - Xiaoxue Xing
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, PR China
6 shared publications Li Chen
Department of Dermatology Huashan Hospital Fudan University Shanghai China
3 shared publicationsShanglin Jin
Department of Dermatology Huashan Hospital Fudan University Shanghai China
3 shared publicationsYiwen Yang
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
3 shared publications
Latest Publications
- 27 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1887-1895.e7
Clinical characteristics, outcome, and costs among patients in a dermatological intensive care unit: A single-center retrospective study
- 27 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1887-1895.e7
Clinical characteristics, outcome, and costs among patients in a dermatological intensive care unit: A single-center retrospective study
- Open Access
- 17 October 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2574307
Long-term efficacy and safety of oral abrocitinib combined with narrow-band UVB phototherapy in non-segmental vitiligo: a 52-week prospective study
Janus kinase (JAK) inhibitors, such as abrocitinib, are emerging alternatives to glucocorticoids for treating progressive non-segmental vitiligo (NSV), though long-term data remain limited. To assess 52-week efficacy and safety of oral abrocitinib with narrow-band ultraviolet B (NB-UVB) phototherapy in progressive NSV. Eleven patients with progressive NSV, resistant to systemic glucocorticoids treatment, received abrocitinib (100 mg/day) for 16 weeks, followed by 100 mg every other day for 36 additional weeks. NB-UVB phototherapy was performed twice weekly. Response was assessed using the Total Vitiligo Area Severity Index (T-VASI) and Facial Vitiligo Area Severity Index (F-VASI). Serum biomarkers and adverse events (AEs) were monitored. Median improvement increased from 29.2% (IQR 8.8%-38.6%) at week 24 to 39.6% (IQR 27.7%-47.8%) at week 52 (p = 0.043). By week 24, 54.5% achieved T-VASI25, improving to 72.7% by week 52. Non-responders at week 24 showed no further improvement at week 52. Serum CCL20 decreased at weeks 24 and 52 (p = 0.0003), while CXCL10 and IFN-γ remained unchanged. Mild AEs (headache, dizziness, nausea) were reported and no severe AE was observed. Long-term abrocitinib plus NB-UVB phototherapy demonstrates sustained efficacy and safety in progressive NSV, though non-responders by 24 weeks may not benefit from extension.
- 17 October 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2574307
Open AccessLong-term efficacy and safety of oral abrocitinib combined with narrow-band UVB phototherapy in non-segmental vitiligo: a 52-week prospective study
Janus kinase (JAK) inhibitors, such as abrocitinib, are emerging alternatives to glucocorticoids for treating progressive non-segmental vitiligo (NSV), though long-term data remain limited. To assess 52-week efficacy and safety of oral abrocitinib with narrow-band ultraviolet B (NB-UVB) phototherapy in progressive NSV. Eleven patients with progressive NSV, resistant to systemic glucocorticoids treatment, received abrocitinib (100 mg/day) for 16 weeks, followed by 100 mg every other day for 36 additional weeks. NB-UVB phototherapy was performed twice weekly. Response was assessed using the Total Vitiligo Area Severity Index (T-VASI) and Facial Vitiligo Area Severity Index (F-VASI). Serum biomarkers and adverse events (AEs) were monitored. Median improvement increased from 29.2% (IQR 8.8%-38.6%) at week 24 to 39.6% (IQR 27.7%-47.8%) at week 52 (p = 0.043). By week 24, 54.5% achieved T-VASI25, improving to 72.7% by week 52. Non-responders at week 24 showed no further improvement at week 52. Serum CCL20 decreased at weeks 24 and 52 (p = 0.0003), while CXCL10 and IFN-γ remained unchanged. Mild AEs (headache, dizziness, nausea) were reported and no severe AE was observed. Long-term abrocitinib plus NB-UVB phototherapy demonstrates sustained efficacy and safety in progressive NSV, though non-responders by 24 weeks may not benefit from extension.
- 5 September 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (5) , e70052
Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases
The term acquired dermal macular hyperpigmentation (ADMH) was introduced to unify Riehl's melanosis (RM), lichen planus pigmentosus (LPP), and related entities. These are cosmetically distressing pigmentary disorders that pose therapeutic challenges. To investigate the efficacy and safety of oral isotretinoin in treating ADMH, we conducted a muticenter retrospective study of patients with ADMH treated with oral isotretinoin between 2014 and 2024. Patients from Australia, China, Europe, India, Middle East, North America, and North Africa were included. Patients lost to follow‐up before two visits were excluded. The response was graded by a 5‐point Investigator's Global Assessment (IGA) scale. A total of 121 patients were included. Most patients (64.5%) were treated with a dose of 20 mg/d for an average of 8 months. Oral isotretinoin improved the severity of pigmentation in all RM and 85 (90.4%) LPP patients, with 17 (63.0%) RM and 31 (33.0%) LPP patients achieving marked improvement. RM patients responded better than LPP patients (p = 0.005). Patients with localized lesions (p = 0.0012), disease duration of less than 5 years (p = 0.046 for RM, p = 0.0272 for LPP), Fitzpatrick skin phototypes III‐VI (p = 0.0081), or longer duration of treatment (p = 0.0178) responded better. Oral isotretinoin appears to be a promising treatment modality for ADMH.
- 5 September 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (5) , e70052
Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi‐Institutional Retrospective Study of 121 Cases
The term acquired dermal macular hyperpigmentation (ADMH) was introduced to unify Riehl's melanosis (RM), lichen planus pigmentosus (LPP), and related entities. These are cosmetically distressing pigmentary disorders that pose therapeutic challenges. To investigate the efficacy and safety of oral isotretinoin in treating ADMH, we conducted a muticenter retrospective study of patients with ADMH treated with oral isotretinoin between 2014 and 2024. Patients from Australia, China, Europe, India, Middle East, North America, and North Africa were included. Patients lost to follow‐up before two visits were excluded. The response was graded by a 5‐point Investigator's Global Assessment (IGA) scale. A total of 121 patients were included. Most patients (64.5%) were treated with a dose of 20 mg/d for an average of 8 months. Oral isotretinoin improved the severity of pigmentation in all RM and 85 (90.4%) LPP patients, with 17 (63.0%) RM and 31 (33.0%) LPP patients achieving marked improvement. RM patients responded better than LPP patients (p = 0.005). Patients with localized lesions (p = 0.0012), disease duration of less than 5 years (p = 0.046 for RM, p = 0.0272 for LPP), Fitzpatrick skin phototypes III‐VI (p = 0.0081), or longer duration of treatment (p = 0.0178) responded better. Oral isotretinoin appears to be a promising treatment modality for ADMH.
- 8 January 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (5)
A rare severe acrodermatitis continua of Hallopeau treated with spesolimab
- 8 January 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (5)
A rare severe acrodermatitis continua of Hallopeau treated with spesolimab
- Open Access
- 3 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-4
Correction: Dysfunction of ATG7-dependent autophagy dysregulates the antioxidant response and contributes to oxidative stress-induced biological impairments in human epidermal melanocytes
- 3 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-4
Open AccessCorrection: Dysfunction of ATG7-dependent autophagy dysregulates the antioxidant response and contributes to oxidative stress-induced biological impairments in human epidermal melanocytes
- 10 June 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (2) , e128-e130
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid‐resistant vitiligo: A prospective case series
- 10 June 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (2) , e128-e130
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid‐resistant vitiligo: A prospective case series
- Open Access
- 8 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2049-2057
Efficacy and safety of the combination of oral tranexamic acid and intense pulsed light versus oral tranexamic acid alone in the treatment of refractory Riehl's melanosis: A prospective, comparative study
BackgroundThere is no standardized and effective treatment modality for Riehl's melanosis.AimsTo compare the efficacy and safety of oral tranexamic acid (TXA) combined with intense pulsed light (IPL) versus TXA alone in the treatment of refractory Riehl's melanosis.MethodsA prospective study of 28 subjects with refractory Riehl's melanosis and Fitzpatrick Skin Types III or IV was conducted. All subjects received oral TXA 500 mg daily and 11 of them were treated in combination with monthly IPL therapy for 6 months. The primary outcome measure was mean melanin index (MI), erythema index (EI) and acquired dermal macular hyperpigmentation area and severity index (DPASI). The Physician Global Assessment (PGA) and patient satisfaction scale were documented.ResultsAfter treatment, DPASI, mean MI, and EI were significantly reduced in both groups. The group treated with combination therapy showed better improvement according to MI (p = 0.0032) and DPASI (p = 0.00468). PGA and patient satisfaction scale showed superior efficacy in the combination group. No significant difference was observed in treatment-related side effects.ConclusionThe combination of oral TXA and IPL proves to be a safe and satisfactory treatment strategy for refractory Riehl's melanosis.
- 8 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2049-2057
Open AccessEfficacy and safety of the combination of oral tranexamic acid and intense pulsed light versus oral tranexamic acid alone in the treatment of refractory Riehl's melanosis: A prospective, comparative study
BackgroundThere is no standardized and effective treatment modality for Riehl's melanosis.AimsTo compare the efficacy and safety of oral tranexamic acid (TXA) combined with intense pulsed light (IPL) versus TXA alone in the treatment of refractory Riehl's melanosis.MethodsA prospective study of 28 subjects with refractory Riehl's melanosis and Fitzpatrick Skin Types III or IV was conducted. All subjects received oral TXA 500 mg daily and 11 of them were treated in combination with monthly IPL therapy for 6 months. The primary outcome measure was mean melanin index (MI), erythema index (EI) and acquired dermal macular hyperpigmentation area and severity index (DPASI). The Physician Global Assessment (PGA) and patient satisfaction scale were documented.ResultsAfter treatment, DPASI, mean MI, and EI were significantly reduced in both groups. The group treated with combination therapy showed better improvement according to MI (p = 0.0032) and DPASI (p = 0.00468). PGA and patient satisfaction scale showed superior efficacy in the combination group. No significant difference was observed in treatment-related side effects.ConclusionThe combination of oral TXA and IPL proves to be a safe and satisfactory treatment strategy for refractory Riehl's melanosis.
- 6 July 2023
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 39 (6) , 663-666
Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow‐band UVB: A case report of 2‐year follow‐up
- 6 July 2023
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 39 (6) , 663-666
Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow‐band UVB: A case report of 2‐year follow‐up
- 4 July 2023
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 36 (6) , 455-467
Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment
Riehl's melanosis is a hyperpigmentation disorder that has a significant psychological and social impact on individuals. In the past 10 years, new categories have been developed, raising questions about how to classify Riehl's melanosis. The mechanism of this disease remains unclear, although the type IV hypersensitivity response caused by allergic sensitization, as well as genetic, ultraviolet radiation, and autoimmune factors, is to blame. Clinical manifestation, dermoscopy, reflectance confocal microscopy, patch/photopatch testing, histopathology, and a novel multimodality skin imaging system have been used for the diagnosis. A variety of therapies including topical skin‐lightening agents, oral tranexamic acid, glycyrrhizin compound, chemical peels, and lasers and light therapies (intense pulsed light, 1064‐nm Q‐Switched Nd: YAG laser, 755‐nm PicoWay laser, nonablative 1927‐nm fractional thulium fiber laser, new pulsed‐type microneedling radiofrequency), with improved effectiveness. The latest findings on possible biomarkers and their relationship to other autoimmune diseases were also summarized.
- 4 July 2023
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 36 (6) , 455-467
Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment
Riehl's melanosis is a hyperpigmentation disorder that has a significant psychological and social impact on individuals. In the past 10 years, new categories have been developed, raising questions about how to classify Riehl's melanosis. The mechanism of this disease remains unclear, although the type IV hypersensitivity response caused by allergic sensitization, as well as genetic, ultraviolet radiation, and autoimmune factors, is to blame. Clinical manifestation, dermoscopy, reflectance confocal microscopy, patch/photopatch testing, histopathology, and a novel multimodality skin imaging system have been used for the diagnosis. A variety of therapies including topical skin‐lightening agents, oral tranexamic acid, glycyrrhizin compound, chemical peels, and lasers and light therapies (intense pulsed light, 1064‐nm Q‐Switched Nd: YAG laser, 755‐nm PicoWay laser, nonablative 1927‐nm fractional thulium fiber laser, new pulsed‐type microneedling radiofrequency), with improved effectiveness. The latest findings on possible biomarkers and their relationship to other autoimmune diseases were also summarized.